World Journal of Neuroscience

Volume 5, Issue 5 (November 2015)

ISSN Print: 2162-2000   ISSN Online: 2162-2019

Google-based Impact Factor: 0.57  Citations  

Mono-Therapy versus Poly-Therapy: Ten Years Indian Experience on Various Seizure Disorders

HTML  XML Download Download as PDF (Size: 262KB)  PP. 350-357  
DOI: 10.4236/wjns.2015.55034    6,284 Downloads   7,624 Views  Citations

ABSTRACT

Objectives: To find out prescription patterns and seizure freedom with different mono-, duo- and poly-therapies used in various seizure disorders in Indian setting. Material and Methods: Subjects with seizures, not responding to first antiepileptic drug, were evaluated prospectively for a period of 6 months. Patients on various dual antiepileptic drugs (AEDs) prescriptions were prospectively analyzed for 1) the pattern and frequency of different duo-therapies; 2) etiological profile of patients in duo-therapy prescription; and 3) frequency of seizure freedom on various duo-therapy groups. Results: Among 2542 patients, 293 (11.5%) lost in follow-up and thus, 2249 (88.5%) were followed. 1324 (58.9%) had seizure freedom on mono-therapy, 532 (23.7%) required duo-therapy and only 45 (2%) were better controlled on poly-therapy. Among the subjects, who were on mono-therapy, Carbamazepine/Oxcarbazepine was the most commonly prescribed in 1285 (50.55%) patients as first drug followed by Valproate compound and Phenytoin. The most common duo-therapy used was combination of Valproate with Lamotregine, followed by Phenytoin and Phenobarbitone. Other mono-therapy and combinations are given in this paper. Conclusions: Duo-therapy was required and found to be effective in 23.7% of Indian patients with epilepsy. Selection of appropriate two drug combination is based on individual approach and overall clinical profile of patient.

Share and Cite:

Goel, D. and Mittal, M. (2015) Mono-Therapy versus Poly-Therapy: Ten Years Indian Experience on Various Seizure Disorders. World Journal of Neuroscience, 5, 350-357. doi: 10.4236/wjns.2015.55034.

Copyright © 2026 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.